1. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics. Geneva: World Health Organization;
2022. Licence: CC BY-NC-SA 3.0 IGO
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral genome. Science 1989; 244: 359-362.
3. Smith, D. B., Bukh, J., Kuiken, C., et al. Classification and genotype / subtype assignments of hepatitis C virüs. https://ictv.global/sg_wiki/flaviviridae/hepacivirüs 03.12.2023 tarihinde erişildi.
4. Catanese MT, Uryu K, Kopp M, et al. Ultrastructural analysis of hepatitis C virüs particles. Proc Natl Acad Sci U S A. 2013;110:9505-10.
5. Grassi G, Di Caprio G, Fimia GM, Ippolito G, Tripodi M, Alonzi T. Hepatitis C virüs relies on lipoproteins for its life cycle. World J Gastroenterol. 2016;22:1953-65.
6. https://www.hepatitisc.uw.edu/page/hcv/biology 03.12.2023 tarihinde erişildi.
7. Dearborn A.D., J. Marcotrigiano. Hepatitis C Virüs structure: defined by what it is not. Cold Spring Harb Perspect Med 2020;10:a036822
8. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virüs. J Gastroenterol 2007; 42:411–423
9. Tabata K, Neufeldt CJ, Bartenschlager R. Hepatitis C Virüs Replication. Cold Spring Harb Perspect Med. 2020 Mar 2;10(3):a037093.
10. Suzuki T. Morphogenesis of infectious hepatitis C virüs particles. Front Microbiol 2012, 3:1-8
11. Meylan E, Curran J, Hofmann K., et al. Cardif is an adaptor protein in the rig-i antiviral pathway and is targeted by hepatitis C virüs. Nature 2005; 437: 1167-72.
12. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virüs protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immünity. Proc Nat Acad
Sci USA 2005; 102: 17717-22.
13. Egger D, Wolk B, Gosert R, et al. Expression of hepatitis C virüs proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76 : 5974-84.
14. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immüne responses. Virol J 2011, 8: 161-171.
15. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virüs 1b. Sensitivity to interferon is conferred by amino acid
substitutions in the NS5A region. J Clin Invest 1995; 96(1): 224–230.
16. Lohmann V, Roos A, Körner F, Koch JO, Bartenschlager R. Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virüs. J Viral Hepat. 2000; 7:
167-74.
17. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virüs. Proc Natl Acad Sci U S A. 1991; 88(8):3392-6. doi: 10.1073/pnas.88.8.3392.
18. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282: 103-107.
19. Shekhtman L, Navasa M, Sansone N, et al. Modeling hepatitis C virüs kinetics during liver transplantation reveals the role of the liver in virüs clearance. eLife 2021; 10:e65297
20. Walker MR, Leung P, Eltahla AA, et al Clearance of hepatitis C virüs is associated with early and potent but narrowly-directed, Envelope-specific antibodies. Sci Rep. 2019; 9(1):13300.
21. Bull RA, Luciani F, McElroy K, et al. Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virüs Infection. PLOS Pathogens 2011; 7(9): e1002243.
22. Jo J, Lohmann V, Bartenschlager R, Thimme R. Experimental models to study the immünobiology of hepatitis C virüs. J Gen Virol. 2011; 92: 477-93.
23. Colpitts C.C., Tsai P-L, Zeisel M.B. Hepatitis C Virüs entry: An intriguingly complex and higly regulated process. Int. J. Mol. Sci. 2020; 21, 2091; doi:10.3390/ijms21062091
24. Hoffman B, Liu Q. Hepatitis C viral protein translation: mechanisms and implications in developing antivirals. Liver Int 2011, 1449-1467.
25. Pfaender S, Helfritz FA, Siddharta A, et al. Environmental Stability and Infectivity of Hepatitis C Virüs (HCV) in Different Human Body Fluids. Front Microbiol. 2018; 9: 504. doi: 10.3389/
fmicb.2018.00504.
26. https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/hepatitis-c-virüs.html 21.12.2023 tarihinde erişildi.
27. World Health Statistics. file:///C:/Users/User/Downloads/9789240051140-eng.pdf 16.12.2023 tarihinde erişildi.
28. Younossi ZM, Wong G, Anstee QM, Henry L. The Global Burden of Liver Disease. Clin Gastroenterol Hepatol. 2023 Jul;21(8):1978-1991.
29. Polaris Observatory HCV Collaborators. Global change in hepatitis C virüs prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022
May;7(5):396-415.
30. Emekdas G, Cavuslu S, Oncul O, Artuk C, Aksoy A. Trends in hepatitis B and hepatitis C virüs among blood donors over 16 years in Turkey. Eur J Epidemiol 2006, 21: 299–305
31. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virüs infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015; 21(11):1020-6.
32. Turkish Viral Hepatitis Prevention and Control Program (2018-2023), Ministry of Health Ed. No 1140, Ankara, 2019.
33. Türkiye Hepatit C Tanı ve Tedavi Kılavuzu 2023. Türk Karaciğer Araştırmaları Derneği ve Viral Hepatitle Savaşım Derneği. https://www.vhsd.org/tr/hepatit-c-kullanim-klavuzu-2-23-p.
10.12.2023’de erişildi.
34. Stasi C, Silvestri C, Voller F. Update on hepatitis C epidemiology. Unaware and untreated infected population could be the key to elimination. SN Comp Clin Med. 2020; 2:2808–2815.
35. Hassanin A, Kamel S, Waked I, Fort M. Egypt’s Ambitious Strategy to Eliminate Hepatitis C Virüs: A Case Study. Global Health: Science and Practice. 2021; 9: 187-200.
36. Karaca, Ç., Çakaloğlu, Y., Demir, K. et al. Risk Factors for the Transmission of Hepatitis C Virüs Infection in the Turkish Population. Dig Dis Sci 2006; 51: 365–369.
37. Gökahmetoğlu S, Polat C, Atalay MA, et al. Healthcare-Related HCV Genotype 4d Infections in Kayseri, Turkey. Turk J Gastroenterol. 2022;33(11):964-970.
38. Shiffman ML. The next wave of hepatitis C virüs: the epidemic of intravenous drug use. Liv Int. 2018; 38: 34–9.
39. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019; 133: 1854-1864.
40. Fabrizi, F.; Cerutti, R.; Messa, P. Updated Evidence on the Epidemiology of Hepatitis C Virüs in Hemodialysis. Pathogens 2021, 10, 1149.
41. Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. Clin Microbiol Rev. 2003;16: 546–68.
42. Alaei A, Alaei K, Waye K, et al. Hepatitis C infection and other drug-related harms among inpatients who injected drugs in Turkey. J Viral Hepat. 2017;24:496-505.
43. Vandelli, C., Renzo, F, Romanò L et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol
2004; 99(5): 855-859.
44. Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virüs among gay and bisexual men: a systematic review. Sexual Health. 2017; 14. 28-41.
45. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virüs: systematic review and meta-analysis.Clin Infect Dis. 2014; 59: 765-773.
46. Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral
regimens. J Hepatol. 2021;75(2):462-473.
47. Spearman CW, Dusheiko GM, Hellard M, Sonderup M, Hepatitis C, The Lancet, 2019; 394: 1451-1466.
48. Simmonds, P. The origin of hepatitis C virüs. Curr. Top. Microbiol. İmmünol. 2013; 369: 1–15.
49. Ciccozzi M, Ciccaglione A-R, Presti AL, et al. Reconstruction of the evolutionary dynamics of the hepatitis C virüs 1b epidemic in Turkey. Infect Genet Evol. 2011;11(5):863-8.
50. González-Candelas F, López-Labrador FX, Bracho MA. Recombination in hepatitis C virüs. Virüses. 2011;3(10): 2006-2024.
51. Daloğlu EA, Parkan ÖM, Erdoğan A ve ark. Damar içi madde bağımlılığı olan ve madde bağımlısı olmayan hastalar arasında hepatit C virüs (HCV) genotiplerinin dağılımı. Mikrobiyol Bul
2021; 55(1):30-40
52. Kulah C, Altindis M, Akyar I, et al. The Prevalence of Mixed Genotype Infections in Turkish Patients with Hepatitis C: a Multicentered Assessment. Clin Lab. 2019; 65(4). doi: 10.7754/Clin.
Lab.2018.180824.
53. Duran AÇ, Çetinkaya ÖK, Sayıner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on Hepatitis C Virüs Genotype Distribution in Western Turkey: Evaluation of Twelve-Year Data.
Turk J Gastroenterol 2020; 31(2): 128-35.
54. Cirit OS, Demir Y, Yıldırım MS, et al. Genotype distribution of hepatitis C virüs in the province of Gaziantep, a 10-year evaluation. Acta Microbiol Immunol Hung. 2023; 70(4): 348-352.
55. Gökahmetoğlu S, Polat C, Atalay MA, et al. Healthcare-related HCV genotype 4d infections in Kayseri, Turkey. Turk J Gastroenterol. 2022;33(11):964-970
56. Cirit OS, Uzala Mızraklı A, et al. Genotyping Distribution of Hepatitis C Virus in Şanlıurfa Province and Effect of Syrian Patients. Viral Hepat J. 2019; 25: 62-66.
57. Li HC, Yang CH, Lo SY. Cellular factors involved in the hepatitis C virüs life cycle. World J Gastroenterol 2021; 27(28): 4555-458
58. Katayama K, Kumagai J, Komiya Y, et al. Titration of hepatitis C virüs in chimpanzees for determining the copy number required for transmission. Intervirology. 2004;47(1):57-64.
59. Ferreira AR, Ramos B, Nunes A, Ribeiro D. Hepatitis C Virüs: Evading the Intracellular Innate İmmünity. J Clin Med. 2020; 9(3):790.
60. Sherwood, A.V., Rivera-Rangel, L.R., Ryberg, L.A. et al. Hepatitis C virüs RNA is 5´-capped with flavin adenine dinucleotide. Nature 2023; 619, 811–818.
61. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virüs. Nature. 2009; 461(7265): 798-801.
62. Lee J, Ou JJ. Hepatitis C virüs and intracellular antiviral response. Curr Opin Virol. 2022; 52: 244-249.
63. Schwerk J, Negash A, Savan R, Gale M Jr. Innate İmmünity in Hepatitis C Virüs Infection. Cold Spring Harb Perspect Med. 2021;11(2):a036988.
64. Amako Y, Munakata T, Kohara M, Siddiqui A, Peers C, Harris M. Hepatitis C virüs attenuates mitochondrial lipid beta-oxidation by downregulating mitochondrial trifunctional protein
expression. J Virol 2015, 89:4092–4101.
65. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virüs Infection: Host–
Virüs Interaction and Mechanisms of Viral Persistence. Cells. 2019; 8(4): 376.
66. Rosen HR, Golden-Mason L. Control of HCV Infection by Natural Killer Cells and Macrophages. Cold Spring Harb Perspect Med. 2020;10(9):a037101.
67. Chaudhry S, Emond J, Griesemer A. İmmüne Cell Trafficking to the Liver. Transplantation. 2019; 103(7): 1323-1337.
68. Cashman SB, Marsden BD, Dustin LB. The Humoral İmmüne Response to HCV: Understanding is Key to Vaccine Development. Front İmmünol. 2014; 5: 550.
69. Kemming J, Thimme R, Neumann-Haefelin C. Adaptive İmmüne Response against Hepatitis C Virüs. Int J Mol Sci. 2020; 21(16): 5644.
70. Law M. Antibody Responses in Hepatitis C Infection. Cold Spring Harb Perspect Med. 2021; 11(3): a036962. doi: 10.1101/cshperspect.a036962.
71. Shoukry, N.H. Towards a Systems İmmünology Approach to Understanding Correlates of Protective İmmünity against HCV. Virüses 2021, 13, 1871.
72. Stuart JD, Salinas E, Grakoui A. İmmüne system control of hepatitis C virüs infection. Curr Opin Virol. 2021; 46: 36-44.
73. Martinello M, Solomon SS, Terrault NA, Dore GJ. Hepatitis C. Lancet. 2023; 402(10407):1085-1096.
74. Hirano J, Yoshio S, Sakai Y, et al. Hepatitis C virüs modulates signal peptide peptidase to alter host protein processing. Proc Natl Acad Sci U S A. 2021; 118(22): e2026184118.
75. Mondelli MU, Ottolini S, Oliviero B, et al. Hepatitis C Virüs and the Host: A Mutual Endurance Leaving Indelible Scars in the Host’s İmmünity. Int J Mol Sci. 2023; 25(1): 268.
76. Manns MP, Buti M, Gane E, et al. Hepatitis C virüs infection. Nat Rev Dis Primers. 2017; 3: 17006.
77. Maruyama H, Shiina S. Pathogenesis of hepatitis C virüs-related hepatocellular carcinoma: evidence from recent studies. J Public Health Emerg. 2021; 5: 30.
78. Natural History of HCV Infection – Evaluation, Staging, and Monitoring of Chronic Hepatitis C – Hepatitis C Online (uw.edu). 29.01.2024 tarihinde erişildi.
79. Milosevic I, Todorovic N, Filipovic A, et al. HCV and HCC Tango-Deciphering the Intricate Dance of Disease: A Review Article. Int J Mol Sci. 2023; 24(22): 16048.
80. Fox RK, Corcorran MA (Authors). Core Concepts – Extrahepatic Conditions Related to HCV infection – Evaluation, Staging, and Monitoring of Chronic Hepatitis C – Hepatitis C Online (uw.
edu). 29.01.2024 tarihinde erişildi.
81. Moretti M, Ferro F, Baldini C, Mosca M, Talarico R. Cryoglobulinemic vasculitis: a 2023 update. Curr Opin Rheumatol 2024; 36(1): 27-34.
82. De Re V, Caggiari L, Garziera M, De Zorzi M, Repetto O. Molecular signature in HCV-positive lymphomas. Clin Dev İmmünol. 2012: 623465
83. Fabrizi F, Messa P, Martin P. Novel evidence on hepatitis C virüs-associated glomerular disease. Kidney Int. 2014; 86(3): 466-9
84. El-Kassas M, Awad A. Metabolic aspects of hepatitis C virüs. World J Gastroenterol 2022; 28(22): 2429- 2436.
85. Ding Y, Li G, Zhou Z, Deng T. Molecular mechanisms underlying hepatitis C virüs infection-related diabetes. Metabolism. 2021; 121: 154802.
86. Negro F. Natural history of hepatic and extrahepatic hepatitis C virüs diseases and impact of interferon-free therapy. Cold Spring Harb Perspect Med 2020;10: a036921.
87. Haykal M, Matsumori M, Saleh A, et al. Diagnosis and treatment of HCV heart diseases, Expert Rev Cardiovasc Ther. 2021;19 (6): 493-499.
88. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology.
2016; 150(7): 1599-1608.
89. O’ Kane R, Hathorn E. Hepatitis C: recent advances and practical management. Frontline Gastroenterology 2023; 14: 415–421.
90. Aygen B, Gürbüz Y, Çetinkaya RA, et al. [Management of chronic hepatitis C virüs infection: A consensus report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical
Microbiology and Infectious Diseases-2023 Update]. Klimik Derg. 2023; 36(Özel Sayı): 43-75. Turkish
91. Gauthiez E, Habfast-Robertson I, Rüeger S, et al. Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. Liver Int 2017;37: 1431-1445
92. Monin MB, Ingiliz P, Lutz T, et al. Low spontaneous clearance rates of recently acquired hepatitis C virüs in human immünodeficiency virüs-positive men who have sex with men (PROBE-C
study). Clin Infect Dis 2023; 76: e607–12
93. New recommendation on hepatitis C virüs testing and treatment for people at ongoing risk of infection: policy brief. World Health Organization 2023, ISBN 978-92-4-007187-2.
94. Walker MR, Leung P, Eltahla AA, et al Clearance of hepatitis C virüs is associated with early and potent but narrowly-directed, Envelope-specific antibodies. Sci Rep. 2019; 9(1):13300
95. Richter SS. Laboratory assays for diagnosis and management of hepatitis C virüs infection. J Clin Microbiol 2002, 40: 4407-4412.
96. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C; HEPATITIS Group. Sensitivity and specificity of third-generation hepatitis C virüs antibody detection assays: an analysis
of the literature. J Viral Hepat. 2001; 8(2): 87-95.
97. Warkad SD, Song KS, Pal D, Nimse SB. Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies. Sensors (Basel). 2019; 19(19): 4257.
98. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med. 2012;157(8):
558-66.
99. Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virüs Infection: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;
165(5): 345-55.
100. Wang Y, Jie W, Ling J, Yuanshuai H. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection. J Clin Lab Anal. 2021; 35(6): e23755
101. Majchrzak M, Bronner K, Laperche S, et al. Multicenter performance evaluation of the Elecsys HCV Duo immunoassay. J Clin Virol. 2022; 156: 105293.
102. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020; 73(5): 1170-1218.
103. Freiman JM, Wang J, Easterbrook PJ, et al. Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. J Hepatol. 2019;71(1):62-70.
104. Morgan JR, Marsh E, Savinkina A, et al. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens:
Evidence from a global data set. J Viral Hepat. 2022;29(6):474-486.
105. Tang W, Tao Y, Fajardo E, et al. Diagnostic Accuracy of Point-of-Care HCV Viral Load Assays for HCV Diagnosis: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2022; 12(5):
1255.
106. González V, Gomes-Fernandes M, Bascuñana E, Casanovas S, Saludes V, Jordana-Lluch E, Matas L, Ausina V, Martró E. Accuracy of a commercially available assay for HCV genotyping and
subtyping in the clinical practice. J Clin Virol. 2013; 58(1): 249-53.
107. Peiffer KH, Kuhnhenn L, Stelzl E, et al. Performance of Three Common Hepatitis C Virüs (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. J Clin Microbiol. 2019;
57(7): e00060-19.
108. Fernández-Caso B, Fernández-Caballero JÁ, Chueca N, et al. Infection with multiple hepatitis C virüs genotypes detected using commercial tests should be confirmed using next generation
sequencing. Sci Rep. 2019; 25; 9(1): 9264.
109. Alqahtani SA, Sulkowski MS. Chronic Hepatitis C: Advances in Therapy and the Remaining Challenges. Med Clin North Am. 2023; 107(3): 423-433.
110. Medina C, García AH, Crespo FI, Toro FI, Mayora SJ, De Sanctis JB. A Synopsis of Hepatitis C Virüs Treatments and Future Perspectives. Curr Issues Mol Biol. 2023; 45(10): 8255-8276.
111. Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 2020; 17(7): 892-902.
112. Wyles DL, Luetkemeyer AF. Understanding Hepatitis C Virüs Drug Resistance: Clinical Implications for Current and Future Regimens. Top Antivir Med. 2017; 25(3): 103-109.
113. Hayes CN, Imamura M, Tanaka J, Chayama K. Road to elimination of HCV: Clinical challenges in HCV management. Liver Int. 2022;42(9):1935-1944.
114. https://www.hcvguidelines.org/evaluate/resistance. 12.02.2024 tarihinde erişildi.
115. Bhattacharya D, Aronsohn A, Price J, Lo Re V; AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating
Hepatitis C Virüs Infection. Clin Infect Dis. 2023: ciad319. doi: 10.1093/cid/ciad319.
116. Çekin AH, Güner R, İnkaya AÇ, Oğuz D, Özdemir O, Tabak ÖF. Modeling the health economic burden of hepatitis C virüs infection in Turkey: Cost-effectiveness of targeted screening. Turk
J Gastroenterol. 2023;34(10):1062-1070